Date:3/31/2008

Securities Act of 1933 and Section 21E of the Securities Act of 1934. These statements may be identified by their use of forward-looking terminology such as "believes", "expects", "will", "plan", "targeting" or similar words. Such forward-looking statements, such as our expectation for continued growth in sales and our expectation that the year will be profitable, involve risks and uncertainties that could cause actual results to differ materially from those projected. Risks and uncertainties that could cause actual results to differ materially from such forward looking statements are, but are not limited to, uncertainties in market demand for the company's products or the products of its customers, future actions by competitors, inability to deliver product on time, inability to implement its growth strategies or to integrate its new operations, inability to make acquisitions, inability to realize synergies from its acquisitions, inability to raise capital, inability to retain key employees, and other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission. The forward looking statements made in this news release are made as of the date hereof and Photonic Products Group, Inc. does not assume any obligation to update publicly any forward looking statement.

PHOTONIC PRODUCTS GROUP, INC AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $ 4,395,945 $ 3,078,052

Accounts receivable (after allowance

for doubtful accounts of $15,000 in

2007 and 2006) 2,181,859 2,396,486

Inventories 2,931,080 2,336,033

Other current assets
'/>"/>

SOURCE Photonic Products Group, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Professor Straufs research is Nature Photonics’ cover article
2. 3-D photonic crystals will revolutionize telecommunications
3. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
4. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
5. Live Demos With Hydrogen, New Fuel Cell Products
6. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
7. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
8. iCAD to Feature New Products and Capabilities at European Congress of Radiology
9. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
10. China Biologic Products Commences Trading on OTC Bulletin Board
11. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products